Abstract：IgA nephropathy (IgAN) is a common cause of end stage renal disease in the world. Any intervention to reduce proteinuria is helpful to slow the progress of IgAN. At present，sometimes complete remission of IgAN with proteinuria cannot be achieved through the use of renin angiotensin system inhibitor, thus other non-immunosuppressant drugs, including fish oil, active vitamin D, Sulodexide, adrenergic inhibitor, aldosterone receptor blockade, statins and so on are often needed. By analyzing the related literature, this paper reviews the progress of non-immunosuppressant therapy for IgAN with residual proteinuria.
胡妍琦 李六生. IgA肾病残余蛋白尿非免疫抑制剂药物治疗进展[J]. 中国医药导报, 2018, 15(15): 34-37.
HU Yanqi LI Liusheng. Progress of non-immunosuppressant therapy for IgA nephropathy with residual proteinuria . 中国医药导报, 2018, 15(15): 34-37.
[1] Morales E，Caro J，Gutierrez E，et al. Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease [J]. Kidney Int，2015，88（6）：1434-1441.
[2] Donadio JV，Grande JP，Bergstralh EJ，et al. The long–term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group [J]. J Am Soc Nephrol，1999，10﹙8﹚：1772-1777.
[3] Ferraro PM，Ferraccioli GF，Gambaro G，et al. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy：a randomized controlled trial [J]. Nephrol Dial Transplant，2009，24﹙1﹚：156-160.
[4] Alexopoulos E，Stangou M，Pantzaki A，et al. Treatment of severe IgA nephropathy with omega-3 fatty acids：the effect of a“very low dose”regimen [J]. Ren Fail，2004，26﹙4﹚：453-459.
[5] Uchiyama-Tanaka Y，Mori Y. Effects of eicosapentaenoic acid supplementation on immunoglobulin A nephropathy [J]. Ther Apher Dial，2010，14﹙3﹚：303-307.
[6] 宋锴，姜山，石永兵，等.鱼油治疗IgA肾病的Meta分析[J].中华肾脏病杂志，2010，26 ﹙6﹚：438-441.
[7] Kidney Disease：Improving Global Outcome（KDIGO）Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis [J]. Kidney Int，2012（suppl 2）：139-274.
[8] He W，Kang YS，Dai C，et al.Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury [J]. J Am Soc Nephrol，2011，22﹙1﹚：90-103.
[9] Li XH，Huang XP，Pan L，et al. Vitamin D deficiency may predict a poorer outcome of IgA nephropathy [J]. BMC Nephrol，2016，17﹙1﹚：164.
[10] Szeto CC，Chow KM，Kwan BC，et al. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy：an uncontrolled trial [J]. Am J Kidney Dis，2008，51﹙5﹚：724-731.
[11] Liu LJ，Lv JC，Shi SF，et al. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy：a randomized controlled trial [J]. Am J Kidney Dis，2012，59﹙1﹚：67-74.
[12] Jin D，Xin Z，Hong PX，et al. Calcitriol in the treatment of IgA nephropathy with non-nephrotic range proteinuria：a meta analysis of randomized controlled trials [J]. Clin Nephrol，2017，87﹙1﹚：21-28.
[13] 丁国华，程晖.舒洛地特抗凝在肾脏疾病中的应用[J].肾脏病与透析肾移植杂志，2012，21﹙10﹚：451-452.
[14] Bang K，Chin HJ，Chae DW，et al. Anti-proteinuric effect of sulodexide in immunoglobulin a nephropathy [J]. Yonsei Med J，2011，52﹙4﹚：588-594.
[15] Yang BY，Lee HS，Song SH，et al. Use of low-dose sulodexide in IgA nephropathy patients on renin–angiotensin system blockades [J]. Kidney Res Clin Pract，2012，31﹙3﹚：163-169.
[16] 欧阳南，杜晓刚，甘华.舒洛地特联合缬沙坦治疗IgA肾病的临床研究[J].第三军医大学报，2010，32﹙18﹚：2025-2028.
[17] Wu MT，Tung SC，Hsu KT，et al. Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease：an open-label prospective trial [J]. JRAAS，2014， 15﹙3﹚：271-277.
[18] Szeto CC，Kwan BC，Chow KM，et al. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin A nephropathy–a randomized cross-over study [J]. PLoS One，2013，8﹙5﹚：e62736.
[19] Tang SC，Lin M，Tam S，et al. Aliskiren combined with losartan in immunoglobulin A nephropathy：an open-labeled pilot study [J]. Nephrol Dial Transplant，2012，27﹙2﹚：613-618.
[20] Chrysostomou A，Pedagogos E，MacGregor L，et al. Double blind placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy，with or without an angiotensinⅡ receptor blocker [J]. Clin J Am Soc Nephrol，2006，1﹙2﹚：252-262.
[21] 张庆娴，李月婷，秦少华，等.ACEI/ARB联合安体舒通治疗IgA 肾病的临床观察[J].北京医学，2012，34﹙5﹚：339-343.
[22] 王卫松，林海英，周忠海，等.血管紧张素转换酶抑制剂和（或）血管紧张素受体阻断剂加用螺内酯治疗IgA肾病[J].中华肾脏病杂志，2011，27﹙5﹚：387.
[23] Katzir Z，Leibovitch E，Vaknin H，et al. Effect of atorvastatin on IgA nephropathy in the rat [J]. Clin Nephrol，2013，79﹙3﹚：214-220.
[24] Lundberg S，Lundah J，Gunnarsso I，et al. Atorvastatin-induced modulation of monocyte respiratory burst in vivo in patients with IgA nephropathy：a chronic inflammatory kidney disease [J]. Clin Nephrol，2010，73﹙3﹚：221-228.
[25] Buemi M，Allegra A，Corica F，et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy [J]. Clin Pharmacol Ther，2000，67﹙4﹚：427-431.
[26] Kano K，Nishikura K，Yamada Y，et al. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria [J]. Clin Nephrol，2003， 60﹙2﹚：85-89.
[27] Moriyama T，Oshima Y，Tanaka K，et al. Statins stabilize the renal function of IgA nephropathy [J]. Ren fail，2014， 36﹙3﹚：356-360.
[28] Rosselli J，Thacker SM，Karpinski JP，et al. Treatment of IgA nephropathy：an update [J]. Ann Pharmacother，2011， 45﹙10﹚：1284-1296.
[29] Tian J，Chen JH，Li Q，et al. Lipid peroxidation in IgA nephropathy and the effect of lipo-prostaglandin E1 [J]. J Nephrol，2005，18﹙3﹚：243-248.
[30] Chen XM，Qiu Q，Tang L，et al. Effects of co-administration of urokinase and benazepril on severe IgA nephropathy [J]. Nephrol Dial Transplant，2004，19﹙4﹚：852-857.
[31] Ye ZM，Zhang L，Xu LX，et al. Probucol combined with valsartan in immunoglobulin a nephropath：a multi-centre，open labelled，randomized controlled study [J]. Nephrology，2014，19﹙1﹚：40-46.
[32] 李雯雯，沈沛成.IgA肾病的中医药研究进展[J].西部中医药，2017，30﹙6﹚：143-146.
[33] 王丽红，陈彤，李薇，等.吗替麦考酚酯联合激素治疗血管炎性IgA肾病患者的效果及对24h尿蛋白、血肌酐等的影响[J].疑难病杂志，2016，15（11）：1143-1146.
2018, Vol. 15 
京公网安备 11010502046598号